HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, allowing for the creation of rich data for artificial intelligence (“AI”), is reporting its financial and operational results for the third quarter ended Sept. 30, 2023. Highlights of the report include the publication of a foundational study demonstrating the ability of HeartBeam’s VECG technology platform to detect the presence of coronary artery occlusions in the “Journal of American College Cardiology”; several new management and board of director appointments; and significant progress made toward key milestones for the company’s VECG device. That progress includes receiving and responding to questions from the U.S. Food and Drug Administration (“FDA”) regarding the initial AIMIGo 510(k) submission; holding a presubmission meeting with the FDA on the second AIMIGo 510(k) submission; and receiving a third patent for the 12-Lead Extended Wear Patch designed for detecting heart attacks and complex cardiac arrythmias.
Key financial numbers reported by the company include R&D expenses for Q3 2023 totaled $1.6 million, compared to $1.6 million for the Q3 2022; general and administrative expenses for the quarter were $2.1 million compared to $2 million for the third quarter of 2022; and net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the same period in 2022. “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said HeartBeam founder and CEO Branislav Vajdic, PhD, in the press release. “We ended the third quarter of 2023 with approximately $19.2 million in cash and cash equivalents, and believe we are in a strong position as we carefully manage spending to extend our runway. Earlier in the year we closed a $26.5 million in common stock-only financing, which we believe will fund our operations into early 2025. We look forward to providing updates on our progress in the months ahead.”
To view the full press release, visit https://ibn.fm/FY2eX
About HeartBeam Inc.
HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform intended for patient use at home. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to assess cardiac symptoms quickly and easily so care can be expedited if required. HeartBeam AIMIGo is the first and only credit card-sized, 12-lead output ECG device coupled with a smartphone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. By collecting 3D signals of the heart’s electrical activity, HeartBeam AIMIGo has the potential to provide unparalleled data for the development of AI algorithms. HeartBeam AIMIGo has not yet been cleared by the U.S. Food and Drug Administration (FDA) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is powered by IBN